PRAX (Praxis Precision Medicines) Total Payout Ratio : 2.80 (As of Apr. 29, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Praxis Precision Medicines Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Praxis Precision Medicines's current Total Payout Ratio is 2.80.

Praxis Precision Medicines Total Payout Ratio Historical Data

The historical data trend for Praxis Precision Medicines's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Praxis Precision Medicines Total Payout Ratio Chart

Praxis Precision Medicines Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Payout Ratio

Get a 7-Day Free Trial

3.25

0.63

0.05

0.74

2.80

Praxis Precision Medicines Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Payout Ratio	Get a 7-Day Free Trial															0.15	4.62	6.61	0.02	1.91

Competitive Comparison of Praxis Precision Medicines's Total Payout Ratio

For the Biotechnology subindustry, Praxis Precision Medicines's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Praxis Precision Medicines's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Praxis Precision Medicines's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Praxis Precision Medicines's Total Payout Ratio falls into.

Save Embed

;

Save Embed

;

Praxis Precision Medicines Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Praxis Precision Medicines's Total Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	511.998	+	0)	/	-182.819
	=	2.80

Praxis Precision Medicines's Total Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	111.95	+	0)	/	-58.679
	=	1.91

Praxis Precision Medicines Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Praxis Precision Medicines's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Praxis Precision Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Praxis Precision Medicines Inc (NAS:PRAX) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

99 High Street, 30th Floor, Boston, MA, USA, 02110

Website

https://www.praxismedicines.com

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Executives

Alex Nemiroff	officer: General Counsel and Secretary	C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Lauren Mastrocola	officer: Principal Accounting Officer	C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Jill Desimone	director	C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Marcio Souza	officer: Chief Executive Officer	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Dean J Mitchell	director	C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Timothy Edwin Kelly	officer: Chief Financial Officer	C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Bsof Parallel Master Fund L.p.	10 percent owner	345 PARK AVENUE, NEW YORK NY 10154
Merit Ester Cudkowicz	director	C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Jeffrey Chodakewitz	director	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL ST., SUITE 101, WATERTOWN MA 02472
Stefan Vitorovic	director	C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Blackstone Holdings I/ii Gp L.l.c.	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
William D Young	director	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Stephen A Schwarzman	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Inc.	10 percent owner	345 PARK AVENUE, NEW YORK NY 10154
Blackstone Group Management L.l.c.	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154